PMID- 27455869
OWN - NLM
STAT- MEDLINE
DCOM- 20170523
LR  - 20181202
IS  - 1432-1173 (Electronic)
IS  - 0017-8470 (Linking)
VI  - 67
IP  - 9
DP  - 2016 Sep
TI  - [Terbinafine : Drug-induced lupus erythematodes and triggering of psoriatic skin 
      lesions].
PG  - 724-31
LID - 10.1007/s00105-016-3844-9 [doi]
AB  - Based on the technical information that oral terbinafine must be used with 
      caution in patients with pre-existing psoriasis or lupus erythematosus, the 
      literature was summarized. Terbinafine belongs to the drugs able to induce 
      subcutaneous lupus erythematosus (SCLE)-with a relatively high risk. The clinical 
      picture of terbinafine-induced SCLE may be highly variable and can also include 
      erythema exsudativum multiforme-like or bullous lesions. Thus, differentiation of 
      terbinafine-induced Stevens-Johnson syndrome or toxic epidermal necrolysis may be 
      difficult. Therefore, terbinafine should be prescribed with caution in patients 
      who show light sensitivity, arthralgias, positive antinuclear antibodies or have 
      a history of SLE or SCLE. Case reports include wide-spread, but mostly 
      nonlife-threatening courses, which did not require systemic therapy with steroids 
      or antimalarials in every case. Terbinafine is also able to induce or to 
      aggravate psoriasis. The latency period seems to be rather short (<4 weeks). 
      Terbinafine therefore is not first choice if a systemic therapy with antimycotics 
      is indicated in a patient with psoriasis or psoriatic diathesis. Azole 
      derivatives according to the guidelines may be used as an alternative.
FAU - Mayser, P
AU  - Mayser P
AD  - , Hofmannstr. 11, 35444, Biebertal, Deutschland. 
      peter.mayser@derma.med.uni-giessen.de.
LA  - ger
PT  - Journal Article
PT  - Review
TT  - Terbinafin : Medikamenteninduzierter Lupus erythematodes und Triggerung 
      psoriatischer Hautveranderungen.
PL  - Germany
TA  - Hautarzt
JT  - Der Hautarzt; Zeitschrift fur Dermatologie, Venerologie, und verwandte Gebiete
JID - 0372755
RN  - 0 (Antifungal Agents)
RN  - 0 (Naphthalenes)
RN  - G7RIW8S0XP (Terbinafine)
SB  - IM
MH  - Antifungal Agents/*adverse effects
MH  - Dose-Response Relationship, Drug
MH  - Drug Eruptions/diagnosis/*etiology/*prevention & control
MH  - Evidence-Based Medicine
MH  - Humans
MH  - Naphthalenes/*adverse effects
MH  - Psoriasis/*chemically induced/diagnosis/*prevention & control
MH  - Terbinafine
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Acute generalized exanthematous pustulosis
OT  - Antifungal agents
OT  - Erythema multiforme
OT  - Light sensitivity
OT  - Psoriasis
EDAT- 2016/07/28 06:00
MHDA- 2017/05/24 06:00
CRDT- 2016/07/27 06:00
PHST- 2016/07/27 06:00 [entrez]
PHST- 2016/07/28 06:00 [pubmed]
PHST- 2017/05/24 06:00 [medline]
AID - 10.1007/s00105-016-3844-9 [pii]
AID - 10.1007/s00105-016-3844-9 [doi]
PST - ppublish
SO  - Hautarzt. 2016 Sep;67(9):724-31. doi: 10.1007/s00105-016-3844-9.